Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: One-year follow-up

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 5, 2009, Pages 2391-2397

  Veritti, Daniele ^a   Lanzetta, Paolo ^a   Perissin, Laura ^a   Bandello, Francesco ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; FLUORESCEIN; HYALURONIC ACID; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHAKIC EYE; POSTERIOR JUXTASCLERAL INFUSION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PTOSIS; REFRACTORY DIABETIC MACULAR EDEMA; RETINA FOVEA; RISK REDUCTION; SIDE EFFECT; SUSPENSION; THICKNESS; TREATMENT DURATION; VISUAL ACUITY; DIABETIC RETINOPATHY; DRUG COMBINATION; EVALUATION; INFUSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; SCLERA; TREATMENT OUTCOME;

AGED; CHONDROITIN SULFATES; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; HYALURONIC ACID; INFUSIONS, PARENTERAL; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCLERA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 65549123001     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2518     Document Type: Article

References (50)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-1806.
4. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology. 1983;90:1301-1317.
5. Bresnick GH. Diabetic macular edema: a review. Ophthalmology. 1986;93:989-997.
6. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:766-785.
7. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology. 1991;98:1594-1602.
8. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986;93:938-950.
9. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142:794-799.
10. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol. 2005;89: 321-326.
11. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
12. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920-927.
13. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 111:218-224, 2004; discussion 224-215.
14. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three- month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049.
15. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, random- ized clinical trial. Ophthalmology. 2006;113:1533-1538.
16. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
17. Westfall AC, Osborn A, Kuhl D, Benz MS, Mieler WF, Holz ER. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol. 2005;123:1075-1077.
18. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340.
19. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-698.
20. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52:37-48.
21. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845-3849.
22. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomog- raphy. Arch Ophthalmol. 2001;119:1135-1142.
23. Chan A, Duker JS. A standardized method for reporting changes in macular thickening using optical coherence tomography. Arch Ophthalmol. 2005;123:939-943.
24. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-Month outcomes. Ophthalmology. 2007;114(12):2162-2167.
25. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
26. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
27. Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on cen- tral macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45:3435-3441.
28. Garcia-Arumi J, Boixadera A, Giralt J, et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol. 2005;89:1112-1114.
29. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41:1186-1191.
30. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
31. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci. 2004;45:238-244.
32. Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macu- lar edema. J Diabetes Complications. 2006;20:246-251.
33. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557-1563.
34. Verma LK, Vivek MB, Kumar A, Tewari HK, Venkatesh P. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocul Pharmacol Ther. 2004;20:277-284.
35. Mawatari Y, Koga T, Inumaru J, Hirata A, Fukushima M, Tanihara H. The effect of subtenon triamcinolone acetonide injection for diabetic macular edema on retinal and choroidal circulation. Am J Ophthalmol. 2005;140:948-949.
36. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol. 2005; 139:290-294.
37. Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Kor J Ophthalmol. 2006;20:205-209.
38. Shimura M, Nakazawa T, Yasuda K, Shiono T, Nishida K. Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol. 2007;91:449-454.
39. Cellini M, Pazzaglia A, Zamparini E, Leonetti P, Campos EC. Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema. BMC Ophthalmol. 2008;8:5.
40. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfo- veal neovascularization in age-related macular degeneration. Ophthalmology. 2006;113:3-13.
41. Jockovich ME, Murray TG, Clifford PD, Moshfeghi AA. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes. Retina. 2007;27:247-252.
42. Sugimoto H, Yamada H, Terada N, et al. Intraarticular injection of high molecular weight hyaluronan for osteoarthritis of the knee: prediction of effectiveness with biological markers. J Rheumatol. 2006;33:2527.
43. Porru D, Cervigni M, Nasta L, et al. Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. Rev Recent Clin Trials. 2008;3: 126-129.
44. Klein RG, Eek BC, O'Neill CW, Elin C, Mooney V, Derby RR. Biochemical injection treatment for discogenic low back pain: a pilot study. Spine J. 2003;3:220-226.
45. Peng YS, Lin SC, Huang SJ, et al. Chondroitin sulfate-based anti-inflammatory macromolecular prodrugs. Eur J Pharm Sci. 2006; 29:60-69.
46. Kuijpers AJ, van Wachem PB, van Luyn MJ, et al. In vitro and in vivo evaluation of gelatin-chondroitin sulphate hydrogels for con- trolled release of antibacterial proteins. Biomaterials. 2000;21: 1763-1772.
47. Watson PG, Young RD. Scleral structure, organisation and disease: a review. Exp Eye Res. 2004;78:609-623.
48. Rada JA, Achen VR, Perry CA, Fox PW. Proteoglycans in the human sclera. Evidence for the presence of aggrecan. Invest Ophthalmol Vis Sci. 1997;38:1740-1751.
49. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2002;134:132-134.
50. Oh IK, Baek S, Huh K, Oh J. Periocular abscess caused by Pseu-dallescheria boydii after a posterior subtenon injection of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol. 2007; 245:164-166.